Literature DB >> 31532736

Clinical Progress Note: Procalcitonin in the Management of Pediatric Lower Respiratory Tract Infection.

Sophie E Katz1, Laura F Sartori2, Derek J Williams3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31532736      PMCID： PMC6827540          DOI： 10.12788/jhm.3301

Source DB:  PubMed          Journal:  J Hosp Med        ISSN： 1553-5592            Impact factor:   2.960


× No keyword cloud information.
  16 in total

1.  Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.

Authors:  Seema Jain; Wesley H Self; Richard G Wunderink; Sherene Fakhran; Robert Balk; Anna M Bramley; Carrie Reed; Carlos G Grijalva; Evan J Anderson; D Mark Courtney; James D Chappell; Chao Qi; Eric M Hart; Frank Carroll; Christopher Trabue; Helen K Donnelly; Derek J Williams; Yuwei Zhu; Sandra R Arnold; Krow Ampofo; Grant W Waterer; Min Levine; Stephen Lindstrom; Jonas M Winchell; Jacqueline M Katz; Dean Erdman; Eileen Schneider; Lauri A Hicks; Jonathan A McCullers; Andrew T Pavia; Kathryn M Edwards; Lyn Finelli
Journal:  N Engl J Med       Date:  2015-07-14       Impact factor: 91.245

2.  Clinical Progress Note: Procalcitonin in the Diagnosis and Management of Community-Acquired Pneumonia in Hospitalized Adults.

Authors:  Justin J Choi; Matthew W McCarthy; Matthew S Simon; Arthur T Evans; Wesley H Self; Marshall J Glesby
Journal:  J Hosp Med       Date:  2019-08-16       Impact factor: 2.960

3.  Procalcitonin as an Early Marker of the Need for Invasive Respiratory or Vasopressor Support in Adults With Community-Acquired Pneumonia.

Authors:  Wesley H Self; Carlos G Grijalva; Derek J Williams; Alison Woodworth; Robert A Balk; Sherene Fakhran; Yuwei Zhu; D Mark Courtney; James Chappell; Evan J Anderson; Chao Qi; Grant W Waterer; Christopher Trabue; Anna M Bramley; Seema Jain; Kathryn M Edwards; Richard G Wunderink
Journal:  Chest       Date:  2016-04-21       Impact factor: 9.410

Review 4.  Procalcitonin: Between evidence and critical issues.

Authors:  Elena Aloisio; Alberto Dolci; Mauro Panteghini
Journal:  Clin Chim Acta       Date:  2019-06-10       Impact factor: 3.786

5.  Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia.

Authors:  David T Huang; Lisa A Weissfeld; John A Kellum; Donald M Yealy; Lan Kong; Michael Martino; Derek C Angus
Journal:  Ann Emerg Med       Date:  2008-03-17       Impact factor: 5.721

6.  Procalcitonin increase after endotoxin injection in normal subjects.

Authors:  P Dandona; D Nix; M F Wilson; A Aljada; J Love; M Assicot; C Bohuon
Journal:  J Clin Endocrinol Metab       Date:  1994-12       Impact factor: 5.958

7.  Identifying targets for antimicrobial stewardship in children's hospitals.

Authors:  Jeffrey S Gerber; Matthew P Kronman; Rachael K Ross; Adam L Hersh; Jason G Newland; Talene A Metjian; Theoklis E Zaoutis
Journal:  Infect Control Hosp Epidemiol       Date:  2013-10-24       Impact factor: 3.254

8.  Serial Procalcitonin as a Predictor of Bacteremia and Need for Intensive Care Unit Care in Adults With Pneumonia, Including Those With Highest Severity: A Prospective Cohort Study.

Authors:  Suzanne M McCluskey; Philipp Schuetz; Michael S Abers; Benjamin Bearnot; Maria E Morales; Debora Hoffman; Shreya Patel; Lauren Rosario; Victor Chiappa; Blair A Parry; Ryan T Callahan; Sheila A Bond; Kent Lewandrowski; William Binder; Michael R Filbin; Jatin M Vyas; Michael K Mansour
Journal:  Open Forum Infect Dis       Date:  2017-01-04       Impact factor: 3.835

9.  Procalcitonin guidance to reduce antibiotic treatment of lower respiratory tract infection in children and adolescents (ProPAED): a randomized controlled trial.

Authors:  Gurli Baer; Philipp Baumann; Michael Buettcher; Ulrich Heininger; Gerald Berthet; Juliane Schäfer; Heiner C Bucher; Daniel Trachsel; Jacques Schneider; Muriel Gambon; Diana Reppucci; Jessica M Bonhoeffer; Jody Stähelin-Massik; Philipp Schuetz; Beat Mueller; Gabor Szinnai; Urs B Schaad; Jan Bonhoeffer
Journal:  PLoS One       Date:  2013-08-06       Impact factor: 3.240

10.  Procalcitonin Accurately Identifies Hospitalized Children With Low Risk of Bacterial Community-Acquired Pneumonia.

Authors:  Chris Stockmann; Krow Ampofo; Jarrett Killpack; Derek J Williams; Kathryn M Edwards; Carlos G Grijalva; Sandra R Arnold; Jonathan A McCullers; Evan J Anderson; Richard G Wunderink; Wesley H Self; Anna Bramley; Seema Jain; Andrew T Pavia; Anne J Blaschke
Journal:  J Pediatric Infect Dis Soc       Date:  2018-02-19       Impact factor: 3.164
View more
  4 in total

1.  Distribution characteristics of serum β2-microglobulin between viral and bacterial lower respiratory tract infections: a retrospective study.

Authors:  Xulong Cai; Qiaolan Xu; Chenrong Zhou; Li Zhou; Qijun Yong; Qing Mu; Yan Cheng; Jiena Wang; Jingjing Xie
Journal:  PeerJ       Date:  2020-08-25       Impact factor: 2.984

2.  Pneumonia Severity in Children: Utility of Procalcitonin in Risk Stratification.

Authors:  Laura F Sartori; Yuwei Zhu; Carlos G Grijalva; Krow Ampofo; Per Gesteland; Jakobi Johnson; Rendie McHenry; Donald H Arnold; Andrew T Pavia; Kathryn M Edwards; Derek J Williams
Journal:  Hosp Pediatr       Date:  2021-02-12

3.  Serum β2-microglobulin may be a viral biomarker by analyzing children with upper respiratory tract infections and exanthem subitum: a retrospective study.

Authors:  Xulong Cai; Qiaolan Xu; Chenrong Zhou; Tongjin Yin; Li Zhou
Journal:  PeerJ       Date:  2021-04-06       Impact factor: 2.984

4.  CON: Procalcitonin does not have clinical utility in children with community-acquired pneumonia.

Authors:  Ritu Banerjee
Journal:  JAC Antimicrob Resist       Date:  2021-10-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.